Status:
UNKNOWN
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Lead Sponsor:
Dokuz Eylul University
Conditions:
Pyoderma Gangrenosum
Hidradenitis Suppurativa
Eligibility:
All Genders
18-90 years
Brief Summary
The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG). In this s...
Detailed Description
Cytokines are key molecules in the pathogenesis of inflammatory diseases. These molecules exert their effects through cell surface receptors and intracellular signaling pathways. Janus kinase/signal t...
Eligibility Criteria
Inclusion
- Pyoderma gangrenosum diagnosed with skin biopsy
- Psoriasis diagnosed with skin biopsy
- Hidradenitis suppurativa diagnosed with skin biopsy
- Skin biopsy in healthy subjects
Exclusion
- \- This is a case-based study and there is no exclusion criteria
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04792957
Start Date
May 1 2022
End Date
July 31 2022
Last Update
March 23 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.